Meeting
2022 ASCO Annual Meeting
Trends in frontline PARP inhibitor maintenance in advanced epithelial ovarian cancer across the United States.
Authors
Erica Huelsmann
Fox Chase Cancer Center, Philadelphia, PA
Erica Huelsmann , Mengying Deng , Elizabeth A. Handorf , Christina Chu , Angela Jain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5581)
DOI
10.1200/JCO.2022.40.16_suppl.5581
Abstract #
5581
Poster Bd #
457
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.
First Author: Genevieve MacAulay Vacheresse
Poster
2021 ASCO Quality Care Symposium
Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings.
First Author: Jinan Liu
Poster
2020 ASCO Virtual Scientific Program
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
First Author: Elena Ioana Braicu
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote